6
Participants
Start Date
January 31, 2008
Primary Completion Date
May 31, 2010
Study Completion Date
September 30, 2010
Decitabine (USAN, INN)
Participants will receive 0.2 mg/kg of decitabine subcutaneously twice a week for 12 weeks. The dose will be reduced for toxicities as needed. The maximum dose of decitabine to be given will be 0.2 mg/kg.
Children's Hospital Philadelphia, Philadelphia
Children's Hospital and Research Center at Oakland, Oakland
University Health Network, Toronto
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Carelon Research
OTHER